SSKN - Strata Skin Sciences expects strong first quarter results

2023-04-12 08:18:57 ET

• Strata Skin Sciences ( NASDAQ: SSKN ) expects revenue in the range of $7.3M - $7.8M for the first quarter of 2023, compared to analysts estimate of $7.9M.
• This would be the medical technology company's strongest first-quarter results since the first quarter of 2016.
• "We are off to a tremendous start in 2023, with 44 devices placed in the first quarter and over 3,000 TheraClearX treatments sold since our official launch in January 2023. In addition to the growth we are experiencing in our organic business, we are gaining solid traction from our acquisition of RaMedical. To date, we have converted 86 Pharos accounts to XTRAC devices, further solidifying our market presence and leadership in the eczema-laser market domestically," stated CEO Bob Moccia.
• The company is expected to reports its full financial results for the quarter in May 2023.

For further details see: